title: Bovine (Bos taurus) Bone Marrow Mesenchymal Cell Differentiation to Adipogenic and Myogenic Lineages.
abstract: OBJECTIVE
  We evaluated the effect of peroxisome proliferator-activated receptor (PPAR) agonists on the differentiation and metabolic features of bovine bone marrow-derived mesenchymal cells induced to adipogenic or myogenic lineages.
  
  
  METHODS
  Cells isolated from 7-day-old calves were cultured in basal medium (BM). For adipogenic differentiation, cells were cultured for one passage in BM and then transferred to a medium supplemented with either rosiglitazone, telmisartan, sirtinol or conjugated c-9, t-11 linoleic acid; for myogenic differentiation, third-passage cells were added with either bezafibrate, telmisartan or sirtinol. The expression of PPARx03B3; (an adipogenic differentiation marker), myosin heavy chain (MyHC; a myogenic differentiation marker) and genes related to energy metabolism were measured by quantitative real-time PCR in a completely randomized design.
  
  
  RESULTS
  For adipogenic differentiation, 20 µM telmisartan showed the highest PPARx03B3; expression (15.58 ± 0.62-fold, p < 0.0001), and differences in the expression of energy metabolism-related genes were found for hexokinase II, phosphofructokinase, adipose triglyceride lipase, acetyl-CoA carboxylase α(ACACα) and fatty acid synthase (p < 0.001), but not for ACACβ (p = 0.4275). For myogenic differentiation, 200 µM bezafibrate showed the highest MyHC expression (73.98 ± 11.79-fold), and differences in the expression of all energy metabolism-related genes were found (p < 0.05).
  
  
  CONCLUSIONS
  Adipocyte and myocyte differentiation are enhanced with telmisartan and bezafibrate, respectively, and energy uptake, storage and mobilization are improved with both.
authors.affiliation: Programa de Posgrado en Ciencias de la Produccix00F3;n y de la Salud Animal, Universidad Nacional Autx00F3;noma de Mx00E9;xico (UNAM), Mexico City, Mexico.
authors.forename: Jesus J
authors.initials: JJ
authors.lastname: Ramírez-Espinosa
authors.forename: Laura
authors.initials: L
authors.lastname: González-Dávalos
authors.forename: Armando
authors.initials: A
authors.lastname: Shimada
authors.forename: Enrique
authors.initials: E
authors.lastname: Piña
authors.forename: Alfredo
authors.initials: A
authors.lastname: Varela-Echavarria
authors.forename: Ofelia
authors.initials: O
authors.lastname: Mora
mesh_terms: D017667:Adipocytes / Q000166:cytology; D050156:Adipogenesis / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D001629:Bezafibrate / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology; D002417:Cattle; D019070:Cell Lineage / Q000502:physiology; D004734:Energy Metabolism / Q000235:genetics* / Q000502:physiology; D008041:Linoleic Acids / Q000494:pharmacology; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D024510:Muscle Development / Q000187:drug effects* / Q000502:physiology; D018995:Myosin Heavy Chains / Q000096:biosynthesis; D009284:Naphthols / Q000494:pharmacology; D047495:PPAR gamma / Q000096:biosynthesis; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D060888:Real-Time Polymerase Chain Reaction; D000077154:Rosiglitazone; D000077333:Telmisartan; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D001549:Benzamides; D001562:Benzimidazoles; D001565:Benzoates; D008041:Linoleic Acids; D009284:Naphthols; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; C439060:sirtinol; D000077154:Rosiglitazone; D018995:Myosin Heavy Chains; D000077333:Telmisartan; D001629:Bezafibrate